Navigation Links
BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality

istered via the coronary artery, as a liquid that is injected during catheterization into the damaged heart muscle. The liquid polymerizes within the tissue and forms a protective scaffold that enhances the mechanical strength of the heart muscle during recovery and repair thereby preventing pathological enlargement of the left ventricle after the heart attack. BL-1040 degrades naturally six weeks after injection.

Patients who have undergone an acute MI (AMI) with severe heart damage are the most likely to benefit from BL-1040. Approximately 40% of AMI patients develop left ventricle dilatation or heart failure, which carries a substantially greater mortality risk. This population includes approximately 380,000 patients in the U.S., with a total estimated U.S. market of over $1.5 billion.

BL-1040 was in-licensed from Ben-Gurion University through its business company BGN Technologies, and was developed by Professor Smadar Cohen and Professor Jonathan Leor from the Department of Biotech and Biomedical Engineering at Ben-Gurion University.

About BioLineRx

BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's current product pipeline consists of 10 compounds, 3 of which are in or impending clinical trials. Its lead product, BL-1020, for the treatment of schizophrenia, successfully completed Phase 1 clinical trials; and BL-1040, for the treatment of damaged heart tissue post myocardial infarction, is expected to enter the clinic in the second quarter of 2007. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.

BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials, regulatory approval and marketing. Partnering with researchers, universi
'"/>




Page: 1 2 3

Related medicine technology :

1. BioLineRx Presents Data From Successful Phase I Trial for BL-1020 in Schizophrenia at American Psychiatric Association Conference
2. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:11/28/2008)...28 German biotech company,Partec ...HIV monitoring and,AIDS patient follow-up diagnos...e year 2008, 2.5 million patient tests have been p...ordable "CyFlow" system, supporting already,more ... introduction of the,Partec innovation, the avera...
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
Breaking Medicine Technology:German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 1Veterans for Americas 28VFA 29 Wounded Warrior Outreach Program Responds to Fort Drum in Aftermath of Report 12408 2New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 1New York Strengthens Emergency Preparedness with Cardinal Health Ventilators 3443 2Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 1Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 1Major scientific push to tackle agricultural productivity and food security in developing world 2285 2Major scientific push to tackle agricultural productivity and food security in developing world 2285 3
(Date:12/2/2008)...NDO, Fla., Dec. 2 MEDai, Inc., hea...olutions provider, has added a new module,to its ...The new stand-alone,module monitors a population,...s and alerts stakeholders when there has been a de... Navigator Guidelines(TM) provides,real-time deci...
(Date:12/2/2008)...inal Special Features MLS Stars and Promotes Healt.../ -- Juniper Content Corporation,s (OTC Bulletin ...astest-growing Spanish-language children,s network... special Juega Como un MLS Pro , the climax of th...ue Soccer, on Sunday, December 7th at 7 PM EST. ,...
(Date:12/2/2008)...cts to File NDA with FDA in Early to Mid-2009 , ... Rx, the developers of PharmFilm(R) technology and...g thin film pharmaceutical products, and Strativa ... of Par Pharmaceutical Companies, Inc. (NYSE: PR...all pivotal bioequivalence studies for a thin film...
(Date:12/2/2008)...IN, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- C...l" or "the Company") (Nasdaq: CSKI ), a leading,... over-the-counter drugs in,the People,s Republic ...(Stanley) Hao was appointed Chief Financial Office...y,s Board of Directors. He replaces Yu-kun Zhang,...
Breaking Medicine News(10 mins):Health News:MEDai Evidence-Based Guideline Reporting Provides Decision Support at Point of Care 2Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 2Health News:MonoSol Rx Successfully Completes Pivotal Bioequivalence Studies for Ondansetron Thin Film NDA 3Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3
...or most teenagers a run up the stairs is simply th...or others the resulting breathlessness// and pound...icting a future vulnerability to panic symptoms. ...f Arkansas psychologist, has found that adolescent...
... certain gonorrhea strain has titillated the curio...enzyme, called prolyliminopeptidase//, which helps...s strain of gonorrhea. The existing diagnostic eva...w strain, making detection of gonorrhea extremely ...
... new research shows that nonsurgical embolization ...ecurrence rate and much quicker recovery than surg...eins in the testicle and scrotum). This condition ...ility problems—and can greatly impact quality of l...
...ew Delhi: India witnesses nearly 1.8 million tuber...menace the government// has cleared Rs. 11.56 bill...(RNTCP)-Phase II. As per government estimates, n...infected with TB bacillus but only 10 percent brea...
Other Medicine News:Health News:Panic may Lead to Serious Mental Health Problems in Adolescents 2Health News:Nonsurgical Therapy Highly Effective for Pain and Infertility in Men 2Health News:Government Allot More Funds for Revised TB Program 2
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: